Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Aug;2(8 Suppl 7):1-12.

Update on the Use of Consensus Interferon in Difficult-to-Treat Hepatitis C Patients: A Review of Selected Posters From Digestive Disease Week May 20-25, 2006 Los Angeles, Calif.With commentary by:Fred Poordad, MDCedars-Sinai Medical CenterLos Angeles, Calif

No authors listed

Update on the Use of Consensus Interferon in Difficult-to-Treat Hepatitis C Patients: A Review of Selected Posters From Digestive Disease Week May 20-25, 2006 Los Angeles, Calif.With commentary by:Fred Poordad, MDCedars-Sinai Medical CenterLos Angeles, Calif

No authors listed. Gastroenterol Hepatol (N Y). 2006 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Daily consensus interferon (CIFN) vs peginterferon (PEG IFN) alfa-2a extended therapy for chronic hepatitis C: sustained virologic response (SVR) rates at 72 weeks.
Figure 2.
Figure 2.
High-dose consensus interferon + ribavirin for hepatitis C resistant to peginterferon and ribavirin: overall response to therapy.
Figure 3.
Figure 3.
Consensus interferon + ribavirin following prior peginterferon + ribavirin: response to treatment (intent-to-treat analysis).
Figure 4.
Figure 4.
Daily consensus interferon + ribavirin following PEG alfa-2a or -2b + ribavirin: end-of-treatment response (ETR) and sustained virologic response (SVR) rates.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. Hepatitis C: Fact Sheet | CDC Viral Hepatitis. [June 14, 2006]. Available at http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm.
    1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714. - PubMed
    1. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004;351:760–768. - PubMed
    1. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–1680. - PubMed
    1. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666–1672. - PubMed

LinkOut - more resources